Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Common Equity (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Common Equity for 15 consecutive years, with $6.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 84.44% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Sep 2025, down 84.44%, and an annual FY2024 reading of $38.9 million, down 12.73% over the prior year.
  • Common Equity was $6.1 million for Q3 2025 at Sanara MedTech, down from $35.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $44.6 million in Q3 2022 and bottomed at $6.1 million in Q3 2025.
  • Average Common Equity over 5 years is $36.9 million, with a median of $39.5 million recorded in 2024.
  • The sharpest move saw Common Equity surged 517.38% in 2021, then crashed 84.44% in 2025.
  • Year by year, Common Equity stood at $30.2 million in 2021, then soared by 38.37% to $41.7 million in 2022, then grew by 6.87% to $44.6 million in 2023, then decreased by 12.73% to $38.9 million in 2024, then plummeted by 84.22% to $6.1 million in 2025.
  • Business Quant data shows Common Equity for SMTI at $6.1 million in Q3 2025, $35.4 million in Q2 2025, and $36.7 million in Q1 2025.